Francis M K, Phinney D G, Ryder K
Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
J Biol Chem. 1995 May 12;270(19):11502-13. doi: 10.1074/jbc.270.19.11502.
The modular ligand-binding domains of steroid receptors have been widely used to generate protein chimeras that are ligand dependent for activity. In a similar manner, we generated a series of conditionally active JunD and c-Fos proteins by fusing their carboxyl (COOH)-terminal ends with a COOH-terminal fragment of the human estrogen receptor (ER) that contains the ligand-binding domain. JunD-ER (DER) and Fos-ER (FER) chimeras with an intact leucine zipper and basic region exhibit hormone-dependent activation of activator protein-1-directed transcription in transient expression assays. One of these fusions, DER, has been examined in detail to determine its mechanism of action. Results from immunoprecipitation experiments with extracts from DER and Fos transfected cells demonstrate that Fos and DER readily form heterodimer complexes. Surprisingly, the formation of Fos:DER heterodimers, and possibly DER homodimers, is estrogen-independent. However, gel shift assays clearly demonstrate that DNA binding to AP1 sites by Fos:DER heterodimers or DER homodimers is estrogen-dependent. Moreover, in the absence of estrogen, the DER protein is an effective inhibitor of Fos-mediated transactivation, and this effect is reversed by the presence of estrogen. Our results indicate that the DER protein is a direct, hormone-reversible inhibitor of Fos and that estrogen controls the conditional positive or dominant negative activities of DER at the level of DNA binding to AP1 sites. Accordingly, clonally derived fibroblast cell lines that stably express the DER protein exhibit reduced entry into the S phase of the cell cycle when quiescent cells are serum stimulated in the absence of estrogen. This is in contrast to the estrogen-treated controls. These results support the hypothesis that AP1 is important for cell cycle progression and provide a unique approach for examining the role of AP1 in this process.
类固醇受体的模块化配体结合结构域已被广泛用于生成对活性具有配体依赖性的蛋白质嵌合体。以类似的方式,我们通过将JunD和c-Fos的羧基(COOH)末端与人雌激素受体(ER)的COOH末端片段融合,该片段包含配体结合结构域,从而生成了一系列条件活性的JunD和c-Fos蛋白。具有完整亮氨酸拉链和碱性区域的JunD-ER(DER)和Fos-ER(FER)嵌合体在瞬时表达试验中表现出对激活蛋白-1介导的转录的激素依赖性激活。其中一种融合体DER已被详细研究以确定其作用机制。来自转染了DER和Fos的细胞提取物的免疫沉淀实验结果表明,Fos和DER很容易形成异二聚体复合物。令人惊讶的是,Fos:DER异二聚体以及可能的DER同二聚体的形成不依赖于雌激素。然而,凝胶迁移试验清楚地表明,Fos:DER异二聚体或DER同二聚体与AP1位点的DNA结合是雌激素依赖性的。此外,在没有雌激素的情况下,DER蛋白是Fos介导的反式激活的有效抑制剂,而雌激素的存在可逆转这种作用。我们的结果表明,DER蛋白是Fos的直接、激素可逆抑制剂,并且雌激素在与AP1位点结合的DNA水平上控制DER的条件性正性或显性负性活性。因此,当静止细胞在没有雌激素的情况下受到血清刺激时,稳定表达DER蛋白的克隆衍生成纤维细胞系进入细胞周期S期的比例降低。这与经雌激素处理的对照相反。这些结果支持了AP1对细胞周期进程很重要的假设,并为研究AP1在此过程中的作用提供了一种独特的方法。